RPL7AP2

Across TCGA pan-cancer cohorts, RPL7AP2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RPL7AP2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RPL7AP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL7AP2 is over-expressed in tumor.

BLCA, HNSC, and COAD are the cancer types where RPL7AP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL7AP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.328	.002	8	view →
HNSC	All	III,IV	+0.153	.002	8	view →
COAD	All	II,III,IV	+0.241	<.001	7	view →
UCEC	All	IV	+0.695	.014	4	view →
LUSC	All	All	+0.191	.001	4	view →
LUAD	All	All	+0.342	<.001	3	view →
PAAD	Male	All	+0.484	.028	2	view →
KICH	All	II,III,IV	+0.262	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RPL7AP2–BLCA

Open the BLCA breakdown →